Track market-moving stories before they get noisy

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© robertcicchetti / Getty Images

Pre-Market Stock Futures: The futures are trading modestly higher after a wild Wednesday that saw the Nasdaq explode higher to close at an all-time high of 24,016, up a hefty 1.60%, while the S&P 500 closed up 0.80% at 7,022, also hitting a brand-new all-time closing high. The small-cap Russell 2000, the leading index this year, finished the day at 2,713, up 0.30%, while the Dow Jones Industrial Average was the only loser, closing at 48,463, down 0.15%. Analysts cited more solid news on the war and positive earnings results from the mega-cap money-center banks and brokerage firms.

Treasury Bonds: The sellers showed up on Wednesday as yields rose across the Treasury curve, and this was no surprise after the big rally in U.S. sovereign debt on Tuesday. With the prospect of interest rate cuts falling, Treasury Secretary Scott Bessent said that while he remains constructive on rate cuts in 2026, they may need to be moved out to later in the year. The 30-year-long bond closed Wednesday at 4.89%, while the benchmark 10-year note was last seen at 4.28%.

Oil and Gas: After some heavy selling across the energy complex on Tuesday, the major benchmarks finished modestly higher on Wednesday. Brent Crude closed at $94.94, up 0.16%, while West Texas Intermediate closed virtually unchanged at $91.29. Natural gas closed the session at $2.61, up 0.41% 

Gold: After a big day on Tuesday for the precious metals, like oil and energy stocks, the sellers emerged on Wednesday, and prices for the top metals both closed lower. Gold was last seen at $4,790, down 1.03%, while the final trade for Silver was reported at $78.86, down 0.69%. The strength in the U.S. dollar was cited as a major reason for the decline, and profit-taking after the strong move over the last week was also a likely culprit.

Crypto: The cryptocurrency markets saw a slight correction yesterday following some big early-week gains, with Bitcoin holding above $74,000. Despite volatility driven by geopolitical tensions, Bitcoin, Ethereum, and some other altcoins remained relatively stable. Needless to say, crypto traders and strategists are monitoring the Middle East, where tensions are influencing price movements, though Bitcoin and Ethereum remain up significantly since the conflict began. At 8 AM EDT, Bitcoin is trading at $74,440, while Ethereum is quoted at $2,333.

24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock. 

Here are some of the top Wall Street analyst upgrades, downgrades, and initiations seen on Thursday, April 16, 2026. 

Upgrades: Blackstone Mortgage Trust Inc. (NYSE: BXMT) | BXMT Price Prediction was upgraded to Overweight from Neutral at JPMorgan, with a $21 target price for the shares. Bread Financial Holdings Inc. (NYSE: BFH) was upgraded to Equal Weight from Underweight at Morgan Stanley, with a $91 target price. Equitable Holdings Inc. (NYSE: EQH) was upgraded to Strong Buy from Market Perform at Raymond James, which has a $58 target price for the stock. Grupo Aeroportuario del Centro Norte SAB De CV (NASDAQ: OMAB) was raised to Buy from Hold at HSBC, with a $134 target price for the company. Okta Inc. (NASDAQ: OKTA) was upgraded to Outperform from Market Perform at Raymond James, which has an $85 target price. Downgrades: Corning Inc. (NYSE: GLW) was downgraded to Neutral from Overweight at JPMorgan, which actually raised the target price for the fiber and display giant to $175 from $115. Federated Hermes Inc. (NYSE: FHI) was downgraded to Underweight from Neutral at JPMorgan, which nudged the price target to $56 from $55. GitLab Inc. (NASDAQ: GTLB) was cut to Neutral from Buy at UBS, which slashed the target price for the stock to $24 from $44. PayPal Holdings Inc. (NASDAQ: PYPL) was downgraded to Neutral from Outperform at Mizuho, which cut the target price for the stock to $50 from $60. Two Harbors Investment Corp. (NYSE: TWO) was downgraded to Underweight from Neutral at JPMorgan, which trimmed the target price for the stock to $11 from $12.50. Initiations: Autoliv Inc. (NYSE: ALV) was initiated with a Buy rating at Bank of America, with a $140 price target. CoreWeave (NASDAQ: CRWV) was started with an Outperform rating at Wolfe Research, which has a $150 target price objective. Dicks Sporting Goods Inc. (NYSE: DKS) was initiated with a Buy rating at BTIG, which has a $300 target price for the retail giant. Equifax Inc. (NYSE: EFX) was initiated with an Overweight rating at Mizuho, which has a $222 target price for the shares. Pfizer Inc. (NYSE: PFE) was initiated with an Outperform rating at CICC, which has a $33 target for the healthcare giant.

Posted by Defense World Staff on Apr 19th, 2026

Equitable Holdings, Inc. (NYSE:EQH – Get Free Report) COO Jeffrey Hurd sold 14,358 shares of the company’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $40.58, for a total transaction of $582,647.64. Following the completion of the sale, the chief operating officer directly owned 84,403 shares of the company’s stock, valued at $3,425,073.74. The trade was a 14.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Equitable Trading Down 0.7% Shares of EQH stock opened at $41.68 on Friday. Equitable Holdings, Inc. has a 52-week low of $35.19 and a 52-week high of $56.61. The company has a debt-to-equity ratio of 16.42, a quick ratio of 0.13 and a current ratio of 0.13. The company has a 50-day simple moving average of $39.98 and a two-hundred day simple moving average of $44.67. The company has a market capitalization of $11.69 billion, a price-to-earnings ratio of -8.65, a PEG ratio of 0.40 and a beta of 1.11.

Equitable announced that its Board of Directors has initiated a share buyback program on Wednesday, February 11th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to purchase up to 7.7% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its stock is undervalued.

Equitable Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 11th. Shareholders of record on Wednesday, March 4th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Wednesday, March 4th. Equitable’s dividend payout ratio is presently -22.41%.

Analyst Upgrades and Downgrades EQH has been the subject of a number of research reports. UBS Group reduced their target price on shares of Equitable from $66.00 to $58.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. JPMorgan Chase & Co. reduced their target price on shares of Equitable from $60.00 to $58.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Barclays reduced their target price on shares of Equitable from $57.00 to $49.00 and set an “overweight” rating for the company in a research report on Wednesday, April 8th. The Goldman Sachs Group set a $60.00 target price on shares of Equitable in a research report on Monday, January 5th. Finally, Mizuho reduced their target price on shares of Equitable from $65.00 to $58.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Equitable currently has an average rating of “Moderate Buy” and an average price target of $56.91.

Get Our Latest Report on EQH

Institutional Inflows and Outflows Several institutional investors and hedge funds have recently bought and sold shares of the business. Parkside Financial Bank & Trust boosted its holdings in Equitable by 9.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,726 shares of the company’s stock worth $130,000 after buying an additional 227 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in Equitable by 9.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,999 shares of the company’s stock worth $143,000 after buying an additional 249 shares during the period. Wilmington Savings Fund Society FSB boosted its holdings in Equitable by 11.7% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 2,634 shares of the company’s stock worth $134,000 after buying an additional 275 shares during the period. Farther Finance Advisors LLC boosted its holdings in Equitable by 12.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,882 shares of the company’s stock worth $137,000 after buying an additional 317 shares during the period. Finally, Clearstead Advisors LLC boosted its holdings in Equitable by 1.3% in the 4th quarter. Clearstead Advisors LLC now owns 25,926 shares of the company’s stock worth $1,235,000 after buying an additional 329 shares during the period. 92.70% of the stock is owned by institutional investors.

Key Equitable News Here are the key news stories impacting Equitable this week:

Positive Sentiment: Raymond James upgraded EQH from “market perform” to “strong-buy” with a $58 price target (implying ~39% upside from current levels), which is a clear bullish catalyst for investors. Raymond James Upgrade Positive Sentiment: Management and counterpart Corebridge have discussed potential share buybacks ahead of the pending Corebridge–Equitable transaction; buyback talk typically supports the share price by reducing float and signaling confidence in valuation. Buybacks & Merger Discussion Neutral Sentiment: Insider sales disclosed (all executed under pre-arranged Rule 10b5‑1 plans): COO Jeffrey Hurd sold 14,358 shares (~$40.58 avg), Nick Lane sold 10,000 shares (~$40.44 avg), and CEO Mark Pearson sold 1,387 shares (~$40.03 avg). Because these were planned 10b5‑1 trades the market impact is muted, but such filings can still raise short-term selling pressure. Filing links: Hurd SEC Filing Lane SEC Filing Pearson SEC Filing Negative Sentiment: Technical and fundamental headwinds: the 50‑day moving average (~$40.06) sits below the 200‑day (~$44.79) and key metrics show negative earnings (negative P/E) and high reported leverage; these factors can limit upside and contribute to continued selling pressure despite positive headlines. Equitable Company Profile (Get Free Report)

Equitable Holdings, Inc (NYSE: EQH) is a leading provider of life insurance, annuities and retirement plan services in the United States. Through its insurance subsidiary, AXA Equitable Life Insurance Company, the firm offers a broad range of permanent and term life insurance products designed to help individuals and families manage risk and build wealth. In addition, Equitable provides fixed, variable and indexed annuity solutions to support income planning in retirement, as well as a suite of group retirement and pension plan services for employers and plan sponsors.

The company also maintains an asset management arm that delivers investment strategies across equities, fixed income and alternative asset classes for both retail and institutional clients.

Featured Stories Five stocks we like better than Equitable

Receive News & Ratings for Equitable Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equitable and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEPhibro Animal Health (NASDAQ:PAHC) CEO Sells $415,923.20 in Stock

NEXT HEADLINE »Velchamy Sankarlingam Sells 7,645 Shares of Zoom Communications (NASDAQ:ZM) Stock

Funding will support robotics education and community engagement for underserved students statewide

INDIANAPOLIS--(BUSINESS WIRE)--TechPoint Youth today announced it has received a $200,000 grant from the Global Technology Industry Association (GTIA) to support the expansion of equitable robotics and STEM programming across Indiana. The funding will help TechPoint Youth reach an additional 10,000 Indiana students, particularly girls, students of color, and youth in under-resourced rural and urban communities, while strengthening educator training and local STEM infrastructure.

Indiana is home to a growing technology economy. Through TechPoint Youth's robotics initiative, STEM Mentor and Xplore programs, the organization has proven that access to hands-on technology education changes student trajectories.

Share Founded to equip and empower the next generation of STEM leaders, TechPoint Youth works to expand equitable access to high-impact robotics and technology education statewide. The funding from GTIA will strengthen those efforts by enabling the organization to deepen its reach into communities that have historically had the least access to quality STEM programming, closing gaps in opportunity and building a more inclusive pipeline of future tech leaders in Indiana.

"This investment from GTIA is a powerful affirmation of what we already know to be true, that every young person deserves the chance to discover their potential and find passion for a future career in STEM," said Jamie Inskeep, President and CEO of TechPoint Youth. "With this funding, we can go further and reach deeper into the communities that need us most. We're grateful to GTIA and its members for recognizing that expanding access to STEM isn't just beneficial for the students themselves, it's also fundamental for developing Indiana's future workforce."

TechPoint Youth is one of 45 nonprofit organizations worldwide to have received a GTIA grant as part of the association's $1.91 million in total charitable giving in 2025. GTIA's charitable investment reinforces the association's commitment to advancing access, equity, education, workforce development, and technology-driven innovation. GTIA has recently announced it is expanding its charitable giving to $5 million in 2026.

Through a significantly expanded philanthropic portfolio, GTIA directed funding and resources to organizations such as TechPoint Youth who are creating measurable social impact across education, healthcare, workforce readiness, and community development.

"Philanthropy has long been central to GTIA's mission," said Kelly Ricker, chief operating officer of GTIA. "In 2025, our members helped us take decisive steps to scale our impact – investing in organizations that use technology to expand opportunities, promote equity and create lasting change. Every advancement we make in our giving programs is driven by the commitment and shared purpose of our member community. Their leadership ensures that innovation truly benefits communities worldwide."

Indiana is home to a growing technology economy, and TechPoint Youth sits at the center of building the workforce that will power it. Through its robotics initiative, STEM Mentor and Xplore programs, and community partnerships, TechPoint Youth has spent years proving that access to hands-on technology K-12 education changes trajectories. This GTIA grant will allow the organization to scale, bringing students into the fold, training more educators, and ensuring that the communities with the most to gain from STEM aren't left behind.

About TechPoint Youth TechPoint Youth is Indiana's leading nonprofit dedicated to inspiring and empowering the next generation of STEM leaders by expanding equitable access to high-impact robotics and technology education statewide. For more information, visit techpointyouth.org.

About the Global Technology Industry Association The Global Technology Industry Association (GTIA) is the only vendor-neutral, 501(c)(6) nonprofit membership community connecting and representing the worldwide IT channel. For more information, visit gtia.org.

The market expects Equitable Holdings, Inc. (EQH - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on May 4, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis company is expected to post quarterly earnings of $1.63 per share in its upcoming report, which represents a year-over-year change of +20.7%.

Revenues are expected to be $4.01 billion, up 5.9% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 3.5% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Equitable Holdings?For Equitable Holdings, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that Equitable Holdings will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Equitable Holdings would post earnings of $1.75 per share when it actually produced earnings of $1.76, delivering a surprise of +0.57%.

Over the last four quarters, the company has beaten consensus EPS estimates two times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Equitable Holdings doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Expected Results of an Industry PlayerAmerican International Group (AIG - Free Report) , another stock in the Zacks Insurance - Multi line industry, is expected to report earnings per share of $1.9 for the quarter ended March 2026. This estimate points to a year-over-year change of +62.4%. Revenues for the quarter are expected to be $6.89 billion, up 4.1% from the year-ago quarter.

The consensus EPS estimate for American International Group has been revised 0.4% lower over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +0.53%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that American International Group will most likely beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

NEW YORK--(BUSINESS WIRE)--Equitable Holdings, Inc. (“Equitable Holdings”, “Holdings”, or the “Company”) (NYSE: EQH) today announced financial results for the first quarter ended March 31, 2026.

“We reported solid first quarter results with Non-GAAP operating earnings per share of $1.62, or $1.68 excluding notable items, up 25% from the prior year quarter. Within our businesses, we continued to see healthy organic growth momentum, highlighted by $1.3 billion of net inflows in Retirement and $2.0 billion of advisory net inflows in Wealth Management. Looking forward, we remain confident in achieving our 2026 guidance of $1.8 billion of cash generation and over 15% growth in earnings per share,” said Mark Pearson, President and Chief Executive Officer.

Mr. Pearson concluded, “I am incredibly excited about the announced merger with Corebridge, which will create a diversified financial services company with leading positions across retirement, life insurance, asset management, and wealth management and accelerate our growth strategy. The transaction will be immediately accretive to earnings per share and cash generation, and we project at least 10% accretion on a run-rate basis by year-end 2028. By leveraging the complementary strengths of Equitable and Corebridge, the combined company will have the scale, product breadth, and distribution platform to deliver superior value to both our customers and shareholders.”

Consolidated Results

First Quarter

(in millions, except per share amounts or unless otherwise noted)

2026

2025

Total Assets Under Management/Administration (“AUM/A”, in billions)

$

1,094

$

1,006

Net income (loss) attributable to Holdings

621

63

Net income (loss) attributable to Holdings per common share

2.14

0.16

Non-GAAP operating earnings

472

421

Non-GAAP operating earnings per common share (“EPS”)

1.62

1.30

As of March 31, 2026, total AUM/A was $1.1 trillion, a year-over-year increase of 9%, driven by positive net flows and higher markets over the prior twelve months.

Net income (loss) attributable to Holdings for the first quarter of 2026 was $621 million compared to $63 million in the first quarter of 2025.

Non-GAAP operating earnings in the first quarter of 2026 were $472 million compared to $421 million in the first quarter of 2025. Adjusting for notable items3 of $19 million, first quarter 2026 Non-GAAP operating earnings were $491 million or $1.68 per share.

As of March 31, 2026, book value per common share including accumulated other comprehensive income (“AOCI”) was $(2.83). Book value per common share excluding AOCI was $19.56. Both of these measures reflect the Company’s 68% ownership stake in AllianceBernstein (“AB”) at book value. Book value per common share excluding AOCI but with AB reflected at fair market value was $34.70.

Business Highlights

First quarter 2026 business segment highlights: Retirement reported net inflows of $1.3 billion and first year premiums of $6.0 billion were up 10% over the prior year. Asset Management (AllianceBernstein or “AB”)4 reported net outflows of $7.1 billion, primarily driven by active equities. The institutional pipeline increased to a record $27.5 billion as of quarter end. Wealth Management (“WM”) reported advisory net inflows of $2.0 billion, with total assets under administration reaching $131 billion. Capital management program: The Company returned $223 million to shareholders in the first quarter, including $76 million quarterly cash dividends and $147 million of share repurchases. The Company remains committed to its 60-70% payout ratio target for 2026. The Company reported cash and liquid assets of $1.2 billion at Holdings5 as of quarter end, which remains above the $500 million minimum target. The combined NAIC RBC ratio was approximately 475% at year end, above the Company’s target of 400%. Delivering shareholder value: The Company has completed the deployment of its $20 billion capital committed to AB. This supports growth in AB’s Private Markets business, which had $85 billion of assets under management as of quarter end. During the first quarter, the Company closed on the acquisition of Stifel Independent Advisors, adding over $9 billion of client assets. On March 26th, the Company announced an agreement to combine with Corebridge Financial in an all-stock merger, creating an industry-leading Retirement, Wealth and Asset Management company. The merger is expected to close by year-end 2026, subject to a shareholder vote and regulatory approvals. The transaction is expected to be immediately accretive to earnings per share and cash generation with 10%+ accretion on a run rate basis by year-end 2028. Business Segment Results

Retirement

(in millions, unless otherwise noted)

Q1 2026

Q1 2025

Total Assets (in billions)6

$

175.7

$

154.6

Segment net flows (in billions)

1.3

1.6

Operating earnings (loss)

396

380

Assets increased by 14%, driven by market performance and net inflows over the prior twelve months. First year premiums of $6.0 billion increased by 10% while net inflows of $1.3 billion were lower than the prior year quarter. Operating earnings of $396 million increased versus the prior year quarter, primarily due to higher fee-based revenue and a lower tax rate. Operating earnings adjusted for notable items7 increased from $385 million in the prior year quarter to $394 million. Notable items of $(2) million in the current period reflect lower net investment income from alternatives, offset by a favorable tax credit. Asset Management

(in millions, unless otherwise noted)

Q1 2026

Q1 2025

Total AUM (in billions)

$

838.6

$

784.5

Segment net flows (in billions)

(7.1

)

2.4

Operating earnings (loss)

140

126

AUM increased by 7% due to market performance over the prior twelve months. Net outflows were $7.1 billion in the quarter, including net outflows of $5.8 billion in Retail and $1.9 billion in Institutional, partially offset by net inflows of $0.6 billion in Private Wealth. Operating earnings increased from $126 million in the prior year quarter to $140 million, due to growth in base fees and a higher ownership percentage of AB. Wealth Management

(in millions, unless otherwise noted)

Q1 2026

Q1 2025

Total AUA (in billions)

$

131.0

$

102.1

Advisory net new assets (in billions)

2.0

2.0

Operating earnings (loss)

55

45

AUA increased by 28% over the last twelve months due to market performance, net inflows and acquired assets from the Stifel transaction. Advisory net inflows were $2.0 billion in the quarter, supported by an 11% year-over-year increase in advisor productivity. Operating earnings increased from $45 million in the prior year quarter to $55 million, primarily due to growth in client assets and advisory fees. Corporate and Other (“C&O”)

The operating loss of $119 million in the first quarter decreased from an operating loss of $130 million in the prior year quarter. After adjusting for notable items8, the operating loss was $98 million versus a loss of $122 million in the prior year quarter.

____________________________

1 This press release includes certain Non-GAAP financial measures. More information on these measures and reconciliations to the most comparable U.S. GAAP measures can be found in the “Use of Non-GAAP Financial Measures” section of this release.

2 Please refer to Exhibit 1 for a detailed reconciliation and definitions related to notable items.

3

Please refer to Exhibit 1 for detailed reconciliation and definitions related to notable items.

4

Refers to AllianceBernstein L.P. and AllianceBernstein Holding L.P., collectively.

5

Excludes c. $195 million of cash at Holdings which is available to AllianceBernstein through its credit facility with Equitable Holdings.

6

Retirement assets includes account value (net of embedded derivatives), spread lending balances and reserves (excluding MRBs)

7

Please refer to Exhibit 1 for a detailed reconciliation and definitions related to notable items.

8

Please refer to Exhibit 1 for a detailed reconciliation and definitions related to notable items.

Exhibit 1: Notable Items

Notable items represent the impact on results from our annual actuarial assumption review, approximate impacts attributable to significant variances from the Company’s expectations, and other items that the Company believes may not be indicative of future performance. The Company chooses to highlight the impact of these items and give Non-GAAP measures less notable items to provide a better understanding of our results of operations in a given period. Certain figures may not sum due to rounding.

Impact of notable items by segment and Corporate & Other:

Three Months Ended March 31,

(in millions)

2026

2025

Non-GAAP Operating Earnings

$

472

$

421

Post-tax adjustments related to notable items:

Retirement

(2

)

5

Asset Management

—

—

Wealth Management

—

—

Corporate & Other

21

8

Non-GAAP Operating Earnings, less Notable Items

$

491

$

434

Impact of notable items by item category:

Three Months Ended March 31,

(in millions)

2026

2025

Non-GAAP Operating Earnings

$

472

$

421

Post-tax adjustments related to notable Items:

Net investment income

32

13

Tax credit

(13

)

—

Non-GAAP Operating Earnings, less Notable Items

$

491

$

434

Earnings Conference Call

Equitable Holdings will host a conference call at 9 a.m. ET on May 5, 2026 to discuss its first quarter 2026 results. The conference call webcast, along with additional earnings materials, will be accessible on the company’s investor relations website at ir.equitableholdings.com. Please log on to the webcast at least 15 minutes prior to the call to download and install any necessary software.

To register for the conference call, please use the following link:
EQH First Quarter 2026 Earnings Call

After registering, you will receive an email confirmation including dial in details and a unique conference call code for entry. Registration is open through the live call. To ensure you are connected for the full call we suggest registering a day in advance or at minimum 10 minutes before the start of the call.

A webcast replay will be made available on the Equitable Holdings Investor Relations website at ir.equitableholdings.com.

About Equitable Holdings

Equitable Holdings, Inc. (NYSE: EQH) is a leading financial services holding company comprised of complementary and well-established businesses, Equitable, AllianceBernstein and Equitable Advisors. Equitable Holdings has $1.1 trillion in assets under management and administration (as of 3/31/2026) and more than 5 million client relationships globally. Founded in 1859, Equitable provides retirement and protection strategies to individuals, families and small businesses. AllianceBernstein is a global investment management firm that offers diversified investment services to institutional investors, individuals and private wealth clients. Equitable Advisors, LLC (Equitable Financial Advisors in MI and TN) has approximately 4,600 duly registered and licensed financial professionals that provide financial planning, wealth management, retirement planning, protection and risk management services to clients across the country.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expects,” “believes,” “anticipates,” “forecasts,” “intends,” “seeks,” “aims,” “plans,” “assumes,” “estimates,” “projects,” “should,” “would,” “could,” “may,” “will,” “shall” or variations of such words are generally part of forward-looking statements. Forward-looking statements are made based on management’s current expectations and beliefs concerning future developments and their potential effects upon Equitable Holdings, Inc. (“Holdings”) and its consolidated subsidiaries. These forward-looking statements include, but are not limited to, statements regarding projections, estimates, forecasts and other financial and performance metrics and projections of market expectations. “We,” “us” and “our” refer to Holdings and its consolidated subsidiaries, unless the context refers only to Holdings as a corporate entity. There can be no assurance that future developments affecting Holdings will be those anticipated by management. Forward-looking statements include, without limitation, all matters that are not historical facts.

These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties, and there are certain important factors that could cause actual results to differ, possibly materially, from expectations or estimates reflected in such forward-looking statements, including, among others: (i) the ability to complete the Proposed Transaction on the timeframe or in the terms currently anticipated or at all, including due to a failure to obtain requisite stockholder, stock exchange, regulatory, governmental or other approvals; (ii) risks related to difficulties, inabilities or delays in integrating the parties’ businesses; (iii) the ability to realize the anticipated benefits of the Proposed Transaction, including estimated run-rate expense synergies and projected cost savings at the time, and to the extent anticipated, as well as expected, operating earnings and cash flow generation; (iv) the occurrence of any event, change or other circumstance that could give rise to the right of either or both parties to terminate the merger agreement; (v) the potential impact of the announcement or consummation of the Proposed Transaction on Equitable or Corebridge’s stock price and on their respective business, contractual and operational relationships (including with regulatory bodies, employees, suppliers, clients and competitors); (vi) risk related to business disruptions from the Proposed Transaction that may harm the business or current plans and operations of either or both parties, including diversion of management time from ongoing business operations; (vii) the risk that the Proposed Transaction and the announcement thereof could have an adverse effect on the operations; (viii) the risk that the Proposed Transaction and the announcement thereof could have an adverse effect on the ability of either or both parties to hire and retain key personnel; (ix) the parties’ ability to raise debt on favorable terms or at all; (x) the outcome of any legal proceedings that may be instituted against Equitable, Corebridge, their new parent company or their respective directors; (xi) restrictions on the conduct of Equitable and Corebridge’s respective businesses prior to the closing of the Proposed Transaction and on each of their ability to pursue alternatives to the Proposed Transaction; (xii) the possibility that the Proposed Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events, or unforeseen or unknown liabilities; (xiii) the potential impact of a downgrade in Equitable or Corebridge’s Insurer Financial Strength ratings or credit ratings or of the new parent company of Equitable and Corebridge following completion of the Proposed Transaction; (xiv) conditions in the financial markets and economy, including the impact of geopolitical conflicts, changes in tariffs and trade barriers, the impact on the Company of a continued shutdown of the U.S. government, and related economic conditions, equity market declines and volatility, interest rate fluctuations, impacts on our goodwill and changes in liquidity and access to and cost of capital; (xv) operational factors, including reliance on the payment of dividends to Holdings by its subsidiaries, protection of confidential customer information or proprietary business information, operational failures by us or our service providers, potential strategic transactions, changes in accounting standards, and catastrophic events, such as the outbreak of pandemic diseases; (xvi) credit, counterparties and investments, including counterparty default on derivative contracts, failure of financial institutions, defaults by third parties and affiliates and economic downturns, defaults and other events adversely affecting our investments; (xvii) our reinsurance and hedging programs; (xviii) our products, structure and product distribution, including variable annuity guaranteed benefits features within certain of our products, variations in statutory capital requirements, financial strength and claims-paying ratings, state insurance laws limiting the ability of our insurance subsidiaries to pay dividends and key product distribution relationships; (xix) estimates, assumptions and valuations, including risk management policies and procedures, potential inadequacy of reserves and experience differing from pricing expectations, amortization of deferred acquisition costs and financial models; (xx) our Asset Management segment, including fluctuations in assets under management and the industry-wide shift from actively-managed investment services to passive services; (xxi) recruitment and retention of key employees and experienced and productive financial professionals; (xxii) subjectivity of the determination of the amount of allowances and impairments taken on our investments; (xxiii) legal and regulatory risks, including federal and state legislation affecting financial institutions, insurance regulation and tax reform; (xxiv) risks related to our common stock and (xxv) general risks, including strong industry competition, information systems failing or being compromised and protecting our intellectual property.

Forward-looking statements, including any financial guidance, should be read in conjunction with the other cautionary statements, risks, uncertainties and other factors identified in Holdings’ filings with the Securities and Exchange Commission. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update or revise any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as otherwise may be required by law.

Forward-looking Non-GAAP Metrics

The Company has presented forward-looking statements regarding Non-GAAP operating earnings, and Non-GAAP operating earnings per share. These non-GAAP financial measures are derived by excluding certain amounts, expenses or income, from the corresponding financial measures determined in accordance with GAAP. The determination of the amounts that are excluded from these non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts recognized in a given period. We are unable to present a quantitative reconciliation of forward-looking adjusted operating earnings per share and payout ratio targeted to non-GAAP operating earnings to their most directly comparable forward-looking GAAP financial measures because such information is not available, and management cannot reliably predict all of the necessary components of such GAAP measures without unreasonable effort or expense. In addition, we believe such reconciliations would imply a degree of precision that would be confusing or misleading to investors. The unavailable information could have a significant impact on the Company’s future financial results. These non-GAAP financial measures are preliminary estimates and are subject to risks and uncertainties, including, among others changes in connection with quarter-end and year-end adjustments. Any variations between the Company’s actual results and preliminary financial data set forth above may be material.

Use of Non-GAAP Financial Measures

In addition to our results presented in accordance with U.S. GAAP, we report Non-GAAP Operating Earnings, and Non-GAAP operating common EPS, each of which is a measure that is not determined in accordance with U.S. GAAP. Management principally uses these Non-GAAP financial measures in evaluating performance because they present a clearer picture of our operating performance and they allow management to allocate resources. Similarly, management believes that the use of these Non-GAAP financial measures, together with relevant U.S. GAAP measures, provide investors with a better understanding of our results of operations and the underlying profitability drivers and trends of our business. These Non-GAAP financial measures are intended to remove from our results of operations the impact of market changes (where there is a mismatch in the valuation of assets and liabilities) as well as certain other expenses which are not part of our underlying profitability drivers or likely to re-occur in the foreseeable future, as such items fluctuate from period-to-period in a manner inconsistent with these drivers. These measures should be considered supplementary to our results that are presented in accordance with U.S. GAAP and should not be viewed as a substitute for the U.S. GAAP measures. Other companies may use similarly titled Non-GAAP financial measures that are calculated differently from the way we calculate such measures. Consequently, our Non-GAAP financial measures may not be comparable to similar measures used by other companies.

We also discuss certain operating measures, including AUM, AUA, AV, policy reserves and certain other operating measures, which management believes provide useful information about our businesses and the operational factors underlying our financial performance.

Non-GAAP Operating Earnings

Non-GAAP Operating Earnings is an after-tax Non-GAAP financial measure used to evaluate our financial performance on a consolidated basis that is determined by making certain adjustments to our consolidated after-tax net income attributable to Holdings. The most significant of such adjustments relates to our derivative positions, which protect economic value and statutory capital, and the variable annuity product MRBs. This is a large source of volatility in net income.

Non-GAAP Operating Earnings equals our consolidated after-tax net income attributable to Holdings adjusted to eliminate the impact of the following items:

Items related to variable annuity product features, which include: (i) changes in the fair value of MRB and purchased MRB, including the related attributed fees and claims, offset by derivatives and other securities used to hedge the MRB which result in residual net income volatility as the change in fair value of certain securities is reflected in OCI and due to our statutory capital hedge program; and (ii) market adjustments to deposit asset or liability accounts arising from reinsurance agreements which do not expose the reinsurer to a reasonable possibility of a significant loss from insurance risk; Investment (gains) losses, which includes credit loss impairments of securities/investments, sales or disposals of securities/investments, realized capital gains/losses and valuation allowances; Net actuarial (gains) losses, which includes actuarial gains and losses as a result of differences between actual and expected experience on pension plan assets or projected benefit obligation during a given period related to pension, other postretirement benefit obligations, and the one-time impact of the settlement of the defined benefit obligation; Other adjustments, which primarily include restructuring costs related to severance and separation, lease write-offs related to non-recurring restructuring activities, net derivative gains (losses) on certain Non-GMxB derivatives, net investment income from certain items including consolidated VIE investments, seed capital mark-to-market adjustments, unrealized gain/losses and realized capital gains/losses from sales or disposals of select securities, certain legal accruals; a bespoke deal to repurchase UL policies from one entity that had invested in numerous policies purchased in the life settlement market, which disposed of the risk of additional COI litigation by that entity related to those UL policies, impact of the annual actuarial assumption updates attributable to LFPB when the majority of the impact relates to the non-core business; and Income tax expense (benefit) related to the above items and non-recurring tax items, which includes the effect of uncertain tax positions for a given audit period and changes to the deferred tax valuation allowance. In the third quarter of 2025, the Company updated its net investment income (“NII”) segment reporting to better align with our GAAP segments, as well as the reporting of our spread lending programs' income and expenses. Previously, direct and allocated segment NII were recorded based on assets tied to statutory asset tagging and net statutory liabilities for allocation. To better align with our GAAP segments, the Company changed the recording methodology for direct NII. It is now based on the book yields of assets tied to specific segments, considering general account values plus reserves, net of embedded derivatives. Indirect NII, which was previously allocated based on net statutory liabilities, is now allocated based on general account values and reserves, net of embedded derivatives. Additionally, revenues and expenses from our spread lending programs are now primarily recorded within the Retirement segment. Previously, spread lending revenues and expenses were recorded in Corporate and Other, with the excess of revenues over expenses allocated to the insurance segments based on net statutory liabilities. Prior periods have been revised to reflect these changes.

Because Non-GAAP Operating Earnings excludes the foregoing items that can be distortive or unpredictable, management believes that this measure enhances the understanding of the Company’s underlying drivers of profitability and trends in our business, thereby allowing management to make decisions that will positively impact our business.

We use the prevailing corporate federal income tax rate of 21% while taking into account any non-recurring differences for events recognized differently in our financial statements and federal income tax returns as well as partnership income taxed at lower rates when reconciling Net income (loss) attributable to Holdings to Non-GAAP Operating Earnings.

The table below presents a reconciliation of Net income (loss) attributable to Holdings to Non-GAAP Operating Earnings for the three months ended March 31, 2026 and 2025:

Three Months Ended March 31,

(in millions)

2026

2025

Net income (loss) attributable to Holdings

$

621

$

63

Adjustments related to:

Variable annuity product features (1)

(386

)

211

Investment (gains) losses

29

14

Net actuarial (gains) losses related to pension and other postretirement benefit obligations

14

11

Other adjustments (2)

148

205

  Income tax expense (benefit) related to above adjustments

41

(92

)

Non-recurring tax items

5

9

Non-GAAP Operating Earnings

$

472

$

421

Non-GAAP Operating EPS

Non-GAAP Operating Earnings per common share is calculated by dividing Non-GAAP Operating Earnings less preferred stock dividends by diluted common shares outstanding. The table below presents a reconciliation of GAAP EPS to Non-GAAP Operating EPS for the three months ended March 31, 2026 and 2025.

Three Months Ended March 31,

(per share amounts)

2026

2025

Net income (loss) attributable to Holdings

$

2.19

$

0.20

Less: Preferred stock dividend

0.05

0.04

Net Income (loss) available to common shareholders

2.14

0.16

Adjustments related to:

Variable annuity product features (1)

(1.36

)

0.68

Investment (gains) losses

0.10

0.04

Net actuarial (gains) losses related to pension and other postretirement benefit obligations

0.05

0.04

Other adjustments (2)

0.53

0.64

  Income tax expense (benefit) related to above adjustments

0.14

(0.29

)

Non-recurring tax items

0.02

0.03

Non-GAAP Operating Earnings

$

1.62

$

1.30

Book Value per common share, excluding AOCI

We use the term “book value” to refer to total equity attributable to Holdings’ common shareholders. Book Value per common share, excluding AOCI, is our total equity attributable to Holdings, excluding AOCI and preferred stock, divided by ending common shares outstanding.

March 31,
2026

December 31,
2025

Book value per common share

$

(2.83

)

$

(4.03

)

Per share impact of AOCI

22.39

22.17

Book Value per common share, excluding AOCI

$

19.56

$

18.14

Other Operating Measures

We also use certain operating measures which management believes provide useful information about our businesses and the operational factors underlying our financial performance.

Account Value (“AV”)

Account value generally equals the aggregate policy account value of our retirement products.

Assets Under Management (“AUM”)

AUM means investment assets that are managed by one of our subsidiaries and includes: (i) assets managed by AB, (ii) the assets in our general account investment portfolio and (iii) the separate account assets of our Retirement and Life businesses. Total AUM reflects exclusions between segments to avoid double counting.

Assets Under Management (“AUA”)

AUA means advisory and brokerage investment assets included in the Company’s Wealth Management segment.

Segment net flows

Net change in segment customer account balances in a period including, but not limited to, gross premiums, surrenders, withdrawals and benefits. It excludes investment performance, interest credited to customer accounts and policy charges.

Consolidated Statements of Income (Loss) (Unaudited)

Three Months Ended March 31,

2026

2025

(in millions)

REVENUES

Policy charges and fee income

$

429

$

636

Premiums

240

304

Net derivative gains (losses)

580

799

Net investment income (loss)

1,284

1,248

Investment gains (losses), net:

Credit and intent to sell losses on available-for-sale debt securities and loans

7

—

Other investment gains (losses), net

(36

)

(14

)

Total investment gains (losses), net

(29

)

(14

)

Investment management and service fees

1,327

1,285

Other income

399

318

Total revenues

4,230

4,576

BENEFITS AND OTHER DEDUCTIONS

Policyholders’ benefits

385

759

Remeasurement of liability for future policy benefits

9

(2

)

Change in market risk benefits and purchased market risk benefits

325

672

Interest credited to policyholders’ account balances

770

678

Compensation and benefits

625

601

Commissions and distribution-related payments

556

501

Interest expense

62

55

Amortization of deferred policy acquisition costs

209

188

Other operating costs and expenses

402

950

Total benefits and other deductions

3,343

4,402

Income (loss) from continuing operations, before income taxes

887

174

Income tax (expense) benefit

(156

)

(24

)

Net income (loss)

731

150

Less: Net income (loss) attributable to the noncontrolling interest

110

87

Net income (loss) attributable to Holdings

621

63

Less: Preferred stock dividends

14

14

Net income (loss) available to Holdings’ common shareholders

$

607

$

49

Earnings Per Common Share

Three Months Ended March 31,

2026

2025

(in millions)

Earnings per common share

Basic

$

2.16

$

0.16

Diluted

$

2.14

$

0.16

Weighted average shares

Weighted average common stock outstanding for basic earnings per common share

281.3

307.8

Weighted average common stock outstanding for diluted earnings per common share

283.8

311.9

Results of Operations by Segment

Three Months Ended March 31,

2026

2025

(in millions)

Operating earnings (loss) by segment:

Retirement

$

396

$

380

Asset Management

140

126

Wealth Management

55

45

Corporate and Other

(119

)

(130

)

Non-GAAP Operating Earnings

$

472

$

421

Select Balance Sheet Statistics

March 31,
2026

December 31,
2025

(in millions)

ASSETS

Total investments and cash and cash equivalents

$

131,583

$

133,466

Separate Accounts assets

130,470

136,544

Total assets

$

310,382

$

317,990

LIABILITIES

Long-term debt

$

3,837

$

3,835

Future policy benefits and other policyholders' liabilities

17,441

17,660

Policyholders’ account balances

132,662

133,433

Total liabilities

$

308,132

$

316,202

EQUITY

Preferred stock

$

1,068

$

1,068

Accumulated other comprehensive income (loss)

(6,300

)

(6,280

)

Total equity attributable to Holdings

273

(74

)

Total equity attributable to Holdings' common shareholders (ex. AOCI)

5,505

5,138

Assets Under Management (Unaudited)

March 31,
2026

December 31,
2025

(in billions)

Assets Under Management

AB AUM

$

838.6

$

866.9

Exclusion for General Account and other Affiliated Accounts

(88.8

)

(87.3

)

Exclusion for Separate Accounts

(48.8

)

(51.0

)

AB third party

$

701.0

$

728.6

Total Company AUM

AB third party

$

701.0

$

728.6

General Account and other Affiliated Accounts (1) (3) (4) (5)

131.6

133.5

Separate Accounts (2) (3) (4) (5)

130.5

136.5

Total AUM

$

963.1

$

998.6

_______________ (1)

“General Account and other Affiliated Accounts” refers to assets held in the general accounts of our insurance companies and other assets on which we bear the investment risk.

(2)

“Separate Accounts” refers to the separate account investment assets of our insurance subsidiaries excluding any assets on which we bear the investment risk.

(3)

As of March 31, 2026 and December 31, 2025, Separate Accounts AUM is inclusive of $7.6 billion and $8.2 billion & General Account AUM is inclusive of $27 million and $28 million, respectively, ceded to Venerable.

(4)

As of March 31, 2026 and December 31, 2025, Separate Accounts AUM is inclusive of $6.8 billion and $7.2 billion & General Account AUM is inclusive of $2.9 billion and $3.0 billion, respectively, ceded to Global Atlantic.

(5)

Includes Advisory, Brokerage and Direct assets included in our Wealth Management segment.

As of March 31, 2026 and December 31, 2025, Separate Accounts AUM is inclusive of $14.5 billion and $15.1 billion & General Account AUM is inclusive of $9.3 billion and $9.3 billion, respectively, ceded to RGA. More News From Equitable Holdings, Inc.

Equitable Holdings, Inc. (EQH - Free Report) reported $3.61 billion in revenue for the quarter ended March 2026, representing a year-over-year decline of 4.5%. EPS of $1.62 for the same period compares to $1.35 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $3.9 billion, representing a surprise of -7.31%. The company delivered an EPS surprise of +1.27%, with the consensus EPS estimate being $1.60.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Equitable Holdings performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Retirement - Net flows: $1.29 billion compared to the $1.57 billion average estimate based on two analysts.Retirement - Total asset value end of period: $175.68 billion compared to the $176.53 billion average estimate based on two analysts.Wealth Management - Advisory net new assets: $2.02 billion versus $2.27 billion estimated by two analysts on average.Wealth Management - Total Wealth Management ending assets: $131.04 billion versus the two-analyst average estimate of $122.29 billion.Revenue- Policy charges, fee income and premiums: $669 million compared to the $674.25 million average estimate based on three analysts.Revenue- Investment management, service fees and other income: $1.68 billion compared to the $1.78 billion average estimate based on two analysts.Segment revenues- Corporate and Other: $525 million versus the two-analyst average estimate of $590.49 million. The reported number represents a year-over-year change of +157.4%.Revenue- Retirement- Policy charges, fee income and premiums: $307 million versus $324.87 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +37.1% change.Revenue- Retirement- Net investment income (loss): $1.19 billion versus the two-analyst average estimate of $1.19 billion. The reported number represents a year-over-year change of +72.2%.Revenue- Retirement- Net derivative gains (losses): $-6 million versus the two-analyst average estimate of $-3.5 million. The reported number represents a year-over-year change of +20%.Revenue- Retirement- Investment management, service fees and other income: $185 million versus the two-analyst average estimate of $186.25 million. The reported number represents a year-over-year change of +117.7%.Revenue- Wealth Management- Net investment income (loss): $3 million compared to the $3.5 million average estimate based on two analysts. The reported number represents a change of 0% year over year.View all Key Company Metrics for Equitable Holdings here>>>

Shares of Equitable Holdings have returned +11.6% over the past month versus the Zacks S&P 500 composite's +10% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

On May 11, 2026, Equitable Holdings Inc (EQH) shares fell 3.8% today, currently priced at $40.99. The stock has traded within a 52-week range of $35.20 to $56.6

NEW YORK--(BUSINESS WIRE)--Equitable Holdings, Inc. (NYSE: EQH), the leading financial services holding company of Equitable, AllianceBernstein and Equitable Advisors, announced today that its Board of Directors has declared a quarterly cash dividend of $0.30 per share of common stock. The dividend on the common stock will be payable June 8, 2026, to shareholders of record at the close of business on June 1, 2026.

The Company’s board also declared the following cash dividends:

Quarterly dividend of $328.125 per share on Series A 5.25% Non-Cumulative Perpetual Preferred Stock, with a liquidation preference of $25,000 per share, which are represented by depositary shares (NYSE: EQH PR A), each representing a 1/1,000th interest in a share of preferred stock, holders of which will receive $0.328125 per depositary share. The dividend will be payable on June 15, 2026, to holders of record as of June 4, 2026. Quarterly dividend of $268.750 per share on Series C 4.30% Non-Cumulative Perpetual Preferred Stock, with a liquidation preference of $25,000 per share, which are represented by depositary shares (NYSE: EQH PR C), each representing a 1/1,000th interest in a share of preferred stock, holders of which will receive $0.26875 per depositary share. The dividend will be payable on June 15, 2026, to holders of record as of June 4, 2026. About Equitable Holdings

Equitable Holdings, Inc. (NYSE: EQH) is a leading financial services holding company comprised of complementary and well-established businesses, Equitable, AllianceBernstein and Equitable Advisors. Equitable Holdings has $1.1 trillion in assets under management and administration (as of 3/31/2026) and more than 5 million client relationships globally. Founded in 1859, Equitable provides retirement and protection strategies to individuals, families and small businesses. AllianceBernstein is a global investment management firm that offers diversified investment services to institutional investors, individuals and private wealth clients. Equitable Advisors, LLC (Equitable Financial Advisors in MI and TN) has approximately 4,600 duly registered and licensed financial professionals that provide financial planning, wealth management, retirement planning, protection and risk management services to clients across the country.

Reference to the 1859 founding applies specifically and exclusively to Equitable Financial Life Insurance Company (NY, NY).

More News From Equitable Holdings, Inc.

Posted by Defense World Staff on Apr 24th, 2026

Farther Finance Advisors LLC grew its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 2,923.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,941 shares of the biotechnology company’s stock after acquiring an additional 11,546 shares during the quarter. Farther Finance Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $793,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 3.3% in the third quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after purchasing an additional 510,798 shares in the last quarter. Avoro Capital Advisors LLC grew its position in Arrowhead Pharmaceuticals by 2.8% in the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock valued at $375,941,000 after purchasing an additional 300,000 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after buying an additional 2,017,489 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares in the last quarter. Finally, Baker BROS. Advisors LP lifted its position in Arrowhead Pharmaceuticals by 77.9% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,670,762 shares of the biotechnology company’s stock worth $57,625,000 after buying an additional 731,588 shares in the last quarter. 62.61% of the stock is owned by institutional investors.

Insider Activity In other news, insider James C. Hamilton sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $64.19, for a total value of $641,900.00. Following the completion of the sale, the insider directly owned 236,958 shares of the company’s stock, valued at $15,210,334.02. This trade represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 3.60% of the stock is currently owned by insiders.

Analyst Ratings Changes Several brokerages have recently weighed in on ARWR. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $78.00 to $100.00 in a report on Tuesday. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 6th. Piper Sandler restated an “overweight” rating and issued a $110.00 price target (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Finally, Chardan Capital boosted their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $83.78.

Get Our Latest Stock Report on ARWR

Arrowhead Pharmaceuticals Stock Up 0.6% Arrowhead Pharmaceuticals stock opened at $74.40 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The company’s 50-day moving average is $62.63 and its 200-day moving average is $57.95. The firm has a market capitalization of $10.42 billion, a PE ratio of 48.63 and a beta of 1.26. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $12.44 and a fifty-two week high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last issued its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The firm had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. During the same quarter last year, the business posted ($1.39) earnings per share. The company’s revenue for the quarter was up 10461.3% on a year-over-year basis. Sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.37 earnings per share for the current year.

Arrowhead Pharmaceuticals Profile (Free Report)

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.

Read More Five stocks we like better than Arrowhead Pharmaceuticals Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECwm LLC Has $3.34 Million Stake in CF Industries Holdings, Inc. $CF

NEXT HEADLINE »Farther Finance Advisors LLC Makes New Investment in SPDR SSGA My2029 Corporate Bond ETF $MYCI

Posted by Defense World Staff on Apr 27th, 2026

B. Metzler seel. Sohn & Co. AG purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 20,695 shares of the biotechnology company’s stock, valued at approximately $1,374,000.

Other institutional investors also recently modified their holdings of the company. M&T Bank Corp lifted its holdings in shares of Arrowhead Pharmaceuticals by 2,569.6% in the fourth quarter. M&T Bank Corp now owns 240,634 shares of the biotechnology company’s stock valued at $15,976,000 after purchasing an additional 231,620 shares in the last quarter. Nordea Investment Management AB lifted its holdings in shares of Arrowhead Pharmaceuticals by 74.5% in the third quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company’s stock valued at $12,661,000 after purchasing an additional 158,937 shares in the last quarter. HBK Sorce Advisory LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $2,823,000. Erste Asset Management GmbH increased its position in shares of Arrowhead Pharmaceuticals by 55.3% in the third quarter. Erste Asset Management GmbH now owns 73,000 shares of the biotechnology company’s stock valued at $2,466,000 after acquiring an additional 26,000 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $287,000. 62.61% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In ARWR has been the topic of a number of recent research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. Chardan Capital lifted their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. B. Riley Financial lifted their target price on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group lifted their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $83.78.

Read Our Latest Research Report on ARWR

Arrowhead Pharmaceuticals Price Performance NASDAQ:ARWR opened at $73.91 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The stock’s 50-day simple moving average is $62.83 and its 200 day simple moving average is $58.51. The company has a market cap of $10.35 billion, a P/E ratio of 48.31 and a beta of 1.26. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $12.44 and a 52-week high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last announced its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The business had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.Arrowhead Pharmaceuticals’s quarterly revenue was up 10461.3% compared to the same quarter last year. During the same period last year, the firm earned ($1.39) EPS. As a group, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.37 EPS for the current fiscal year.

Insider Buying and Selling In other Arrowhead Pharmaceuticals news, CFO Daniel Joseph Apel sold 13,095 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer owned 162,905 shares of the company’s stock, valued at $11,623,271.75. The trade was a 7.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the transaction, the insider directly owned 226,958 shares in the company, valued at approximately $17,021,850. This trade represents a 4.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 33,095 shares of company stock worth $2,326,228. Company insiders own 3.60% of the company’s stock.

About Arrowhead Pharmaceuticals (Free Report)

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.

Recommended Stories Five stocks we like better than Arrowhead Pharmaceuticals Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEB. Metzler seel. Sohn & Co. AG Sells 23,750 Shares of Carrier Global Corporation $CARR

NEXT HEADLINE »B. Metzler seel. Sohn & Co. AG Cuts Position in BridgeBio Pharma, Inc. $BBIO

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

BofA Securities 2026 Healthcare Conference – May 12-14, 2026

Type: Investor Group Dinner
Date/Time: May 12, 2026

Type: Fireside Chat Presentation
Date/Time: May 13, 2026, 10:00 am PDT

TIDES USA Oligonucleotide & Peptide Therapeutics – May 11-14 in Boston, Massachusetts

Title: Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS with TRiM™ SC
Date/Time: May 13, 2026, 4:45 PM EDT
Presenter: Kayal Madhivanan

33rd European Congress on Obesity (ECO 2026) – May 12-15 in Istanbul, Türkiye

Title: Elevated Activin E levels correlate with insulin resistance and metabolic dysfunction in non-human primates and adult patients with obesity and type 2 diabetes
Date/Time: May 13-14; 1:00 PM – 3:00 PM
Presenter: Jane Kerr, MBChB, MPH, DRCOG

2026 RBC Capital Markets Global Healthcare Conference – May 19-20, 2026

Type: Fireside Chat Presentation
Date/Time: May 20, 2026, 9:00 am EDT

European Atherosclerosis Society (EAS 2026) Congress – May 24-27 in Athens, Greece

2 Oral Presentations:

Title: PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF PLOZASIRAN IN SUBJECTS WITH RENAL OR HEPATIC IMPAIRMENT
Session: Late Breaker Clinical Abstracts
Date/Time: May 26, 2026, 5:00 AM – 5:15 PM
Presenter: Jennifer Hellawell, MD

Title: A CASE REPORT OF A PREGNANT WOMAN WITH FAMILIAL CHYLOMICRONEMIA SYNDROME TREATED WITH PLOZASIRAN, A SMALL INTERFERING RNA AGAINST APOC3
Session: EAS stage: Outreach and case presentations
Date/Time: May 26, 2026, 8:30 AM – 10:30 AM
Presenter: Ann Mertens, MD

European Association for the Study of the Liver (EASL 2026) – May 27-30 in Barcelona, Spain

Title: ARO‑INHBE demonstrates clinically meaningful reductions in liver fat as monotherapy and in combination with low-dose tirzepatide in adults with obesity
Late Breaker Poster Session
Presenter: Rinki Murphy, MBChB, PhD

Presentation materials and webcast links, if applicable, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.

For more information, please visit arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company’s email list and receive news directly, please visit ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

More News From Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript

Want Diversified Upside in Biotechnology? Check out LABUArrowhead Pharmaceuticals NASDAQ: ARWR is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation with BofA pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference.

Anzalone described Arrowhead as an “and” company rather than an “or” company, saying the company intends to build its commercial capabilities without slowing its research operations. He said Arrowhead can now address seven different cell types, with five currently in clinical studies, and remains focused on RNAi innovation.

Get ARWR alerts:

The company also expects several pipeline readouts later this year, including initial data from its dimer, or bispecific, platform and from its CNS platform.

REDEMPLO Launch Off to a Faster-Than-Expected Start A major focus of the discussion was REDEMPLO, Arrowhead’s commercial launch in familial chylomicronemia syndrome, or FCS. Anzalone said the launch “has gone well so far,” noting that Arrowhead had recorded more than 400 prescriptions after one full quarter of sales. He said adoption has been “a bit more rapid” than the company expected.

Anzalone emphasized that FCS remains an education market. While some patients with genetic FCS are diagnosed, he said Arrowhead believes that group represents a small portion of the broader FCS population. The company is also focused on patients with clinical FCS, who do not have known genetic mutations associated with traditional FCS but still have very high triglycerides and a substantially increased risk of pancreatitis.

He said many patients currently categorized as having severe hypertriglyceridemia, or sHTG, may be more appropriately diagnosed as having clinical FCS. That overlap, he said, is informing Arrowhead’s approach as it looks toward a broader sHTG opportunity.

SHASTA Data Expected in Third Quarter Arrowhead is awaiting pivotal data from the SHASTA-3 and SHASTA-4 studies in sHTG, with topline results expected after last patient, last visit near the end of June and subsequent database lock and analysis. Anzalone said the primary endpoint is triglyceride lowering and expressed confidence based on prior experience.

“This essentially works in 100% of people,” Anzalone said, referring to triglyceride reduction in the company’s FCS phase 3 study, where he said there were no non-responders. He contrasted that with what he described as about 20% non-responders for a competitor’s product.

The company is also watching whether the studies show a reduction in acute pancreatitis, a key secondary endpoint. Anzalone said Arrowhead was encouraged by pancreatitis data from competitor Ionis and is “cautiously optimistic” that SHASTA-3 and SHASTA-4 may show a benefit. However, he noted that the event numbers are relatively small and that “funny things can happen with small numbers.”

Arrowhead also has SHASTA-5, an ongoing event-driven study designed to show an improvement in pancreatitis. Anzalone said if SHASTA-3 and SHASTA-4 show a pancreatitis benefit, Arrowhead could decide to stop SHASTA-5, but no decision has been made. He said the timing for SHASTA-5 is difficult to predict because it is event-driven.

Anzalone said pancreatitis data would not be gating for U.S. payers, in Arrowhead’s view, but could matter more outside the United States, where some geographies may require acute pancreatitis data on the label for reimbursement.

Pricing and Market Opportunity Gerberry asked about pricing dynamics in a two-player APOC3-modulating market that includes Ionis’ TRYNGOLZA. Anzalone said Arrowhead does not expect to aggressively discount REDEMPLO and views the product less as a triglyceride-lowering drug and more as a pancreatitis drug.

He said Arrowhead is comfortable with a list price at a slight premium to TRYNGOLZA, citing quarterly dosing, safety profile and historical triglyceride reduction. Anzalone said he believes the sHTG market can support two competitors and that having two companies educating physicians and payers may help the category develop more rapidly.

Asked about peak U.S. sales potential, Anzalone said he would be “a bit more aggressive” than a $3 billion peak estimate referenced by Gerberry, saying he sees a potential $3 billion to $4 billion peak for REDEMPLO. However, he cautioned that the market will take time to develop because of the need for physician education.

Obesity and Cardiometabolic Pipeline Arrowhead also discussed ARO-INHBE, an obesity-related program the company is studying in combination with GLP-1 therapies. Anzalone said Arrowhead has long viewed INHBE as a potential combination therapy rather than a monotherapy.

He said early data in an obese diabetic population showed a doubling of fat reduction and a tripling of liver fat reduction, which he called “eye-opening.” Arrowhead is designing phase 2 studies and expects to begin them this year, with plans to study INHBE as a potential MASH therapy and obesity therapy.

Anzalone also highlighted ARO-ALK7, which targets the Activin E/ALK-7 axis. He said Arrowhead expects more data in the second half of this year and is interested in safety, target knockdown, potential weight loss effects and fat distribution. He said successful adipose delivery in humans could open additional targets and potential dimer approaches.

Arrowhead also expects data from its PCSK9/APOC3 dimer in the third quarter. Anzalone said the company believes the program could address roughly 20 million people in the U.S. with mixed hyperlipidemia.

CNS Platform and Capital Position Anzalone said Arrowhead expects initial data from ARO-MAPT, its first subcutaneously administered CNS drug, later this year. The initial readout will be in healthy volunteers and will focus on whether animal results translate to humans, including tau knockdown and tolerability.

If the readout is positive, Anzalone said Arrowhead could move quickly into additional CNS programs, with multiple candidates potentially entering clinical studies in 2027 and possibly one by late 2026.

On partnering, Anzalone said Arrowhead reported about $1.8 billion in cash on its most recent quarterly update and is positioned to advance its current programs itself. He said the company currently has no interest in partnering plozasiran, zodasiran or the PCSK9/APOC3 dimer, though he acknowledged that partnership views could change in the future.

About Arrowhead Pharmaceuticals NASDAQ: ARWRArrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Want Diversified Upside in Biotechnology? Check out LABUArrowhead Pharmaceuticals NASDAQ: ARWR executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conference.

Vince Anzalone, Arrowhead’s vice president of investor relations, said the company is “on the most solid footing” in its history, citing regulatory progress for REDEMPLO and a strengthened balance sheet. He said the product, approved by the U.S. Food and Drug Administration in November of last year, has since received approval in China, Australia and Canada, as well as a positive CHMP opinion in Europe. Arrowhead expects European Commission approval shortly, he said.

Get ARWR alerts:

Anzalone also pointed to the company’s first full quarter of commercial sales for REDEMPLO, which he characterized as encouraging. He said dynamics in the market for FCS, the rare portion of severe hypertriglyceridemia, are favorable for both Arrowhead and its competitor.

SHASTA-3 and SHASTA-4 Readout Expected in Q3 The most closely watched near-term catalyst discussed at the conference was the expected readout from SHASTA-3 and SHASTA-4, Phase 3 studies evaluating Arrowhead’s therapy in severe hypertriglyceridemia. Anzalone said the company expects to complete the studies toward the end of June, with data expected in the third quarter.

James Hamilton, Arrowhead’s chief medical officer, said the company remains “cautiously optimistic” that the studies will show statistical significance on acute pancreatitis. He said Arrowhead is confident the studies will be sufficiently powered based on blinded event rates.

Hamilton also discussed a change in how acute pancreatitis events are adjudicated. Arrowhead moved from the strict Atlanta criteria used in the PALISADE study to a modified approach that includes definite, probable and possible acute pancreatitis events. He said the change was made before any acute pancreatitis events were adjudicated and does not alter the statistical analysis.

The modified scale, Hamilton said, has been accepted by regulators in the U.S. and Europe, key opinion leaders and major journals. He added that it is the same scale used by Arrowhead’s competitor, which may allow for more direct comparison.

Anzalone said that after the last patient’s last visit, Arrowhead will need to lock the database and conduct the analysis, a process he described as typically taking four to eight weeks.

SHASTA-5 Positioned as Additional Support Arrowhead also discussed SHASTA-5, a study designed specifically to evaluate acute pancreatitis events as the primary endpoint in high-risk patients. Hamilton described the trial as a “belt and suspenders” approach that could help with payers, particularly because it is focused on acute pancreatitis.

Hamilton said enrollment has picked up after the company broadened entry criteria. Initially, patients needed stricter triglyceride and acute pancreatitis history requirements. The revised criteria include at least one acute pancreatitis event within the past five years, a history of triglycerides above 880 and screening triglycerides above 500. Hamilton said the broader criteria should help identify more eligible patients without losing the ability to capture events.

Hamilton said data from SHASTA-5 could arrive in late 2027 or early 2028, though he cautioned that timing is difficult to predict because the trial is event-driven. Anzalone emphasized that SHASTA-5 is not required for submission for approval in severe hypertriglyceridemia, either in the U.S. or abroad.

Safety Signals and Commercial Opportunity Executives addressed investor questions about liver fat and hemoglobin A1c signals seen in the broader APOC3 drug class. Hamilton said Arrowhead has not yet seen unblinded liver fat data from SHASTA-3 and SHASTA-4. He said the company’s hypothesis is that liver fat increases observed by a competitor may be more related to the competitor’s antisense oligonucleotide than to the target itself, though he did not rule out an on-target mechanism.

Hamilton said Arrowhead did not see an increase in liver fat at the 25-milligram dose being used as the go-to-market dose in pivotal studies. At a 50-milligram dose in an earlier study, he said there was about a 2% absolute increase in liver fat. Anzalone said the 25-milligram dose was selected because it appeared maximally active, not due to safety concerns.

On hemoglobin A1c, Hamilton said the company has seen an approximately 0.25% absolute increase, mostly in patients who were diabetic at baseline. He said the issue is generally manageable through adjustments to diabetes medications.

Anzalone said Arrowhead continues to view REDEMPLO as a $3 billion to $4 billion peak revenue opportunity. He said discussions with physicians and payers have reinforced the company’s belief that the APOC3 class is viewed as valuable, adding that some sell-side analysts now estimate the overall class could reach $9 billion to $10 billion annually.

Pipeline Focus Remains Cardiometabolic Beyond REDEMPLO, Anzalone said Arrowhead has about $1.8 billion in cash and is positioned to support a broad development agenda. He highlighted zodasiran as the company’s hoped-for second approved product and said Arrowhead expects a readout later this year for a dual-function molecule designed to silence PCSK9 and APOC3 for mixed hyperlipidemia.

Hamilton also discussed Arrowhead’s ARO-INHBE program, noting that monotherapy weight loss has been modest, while reductions in liver fat and visceral fat have been more notable. He said the strongest weight-loss signal appeared in combination with tirzepatide in patients with type 2 diabetes, a group that can be harder to treat with GLP-1 therapies alone. Hamilton said Arrowhead is still evaluating regulatory endpoints for combination therapy in weight loss, including whether visceral fat reduction could support a path forward.

Asked about Biogen’s recent tau data, Hamilton said the results were generally supportive of the tau hypothesis, particularly because Biogen is moving the molecule into Phase 3. He said Arrowhead’s own approach uses siRNA-mediated knockdown and subcutaneous dosing rather than intrathecal administration, which he described as a potential advantage.

Anzalone said Arrowhead’s capital allocation will be increasingly weighted toward cardiometabolic programs, while the company may be more aggressive in partnering non-core assets. He said the company has more than 20 drugs in clinical studies and recently completed a deal with Madrigal on a MASH asset targeting PNPLA3.

About Arrowhead Pharmaceuticals NASDAQ: ARWRArrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

-

- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment

- Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the term of a pregnancy

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented new positive clinical data for plozasiran supporting its use in patients with moderate-to-severe renal impairment or moderate hepatic impairment without the need for dose adjustment, and a case report suggesting that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride (TG) levels through the term of a pregnancy. The data were presented in two oral presentations at the 94th European Atherosclerosis Society (EAS) Congress, taking place in Athens, Greece from May 24-27.

Patients living with extremely high triglycerides often suffer from significant comorbidities. Today’s data represent an important step in bridging the gap between patient needs and scientific innovation.

Share “Patients living with extremely high triglycerides often suffer from significant comorbidities. Today’s data represent an important step in bridging the gap between patient needs and scientific innovation,” said Jennifer Hellawell, MD, board-certified cardiologist and Vice President of Clinical Development at Arrowhead Pharmaceuticals. “As a physician at heart, I’m proud to be part of the team advancing next-generation therapies for this underserved community. We’re excited to have better characterized the PK and PD of plozasiran in this potentially broader patient population. These data bring us closer to delivering meaningful impact for patients.”

Plozasiran is a small interfering RNA (siRNA) medicine designed to reduce hepatic production of apolipoprotein C‑III (APOC3) through targeted RNA interference. It received regulatory approval in the United States, China, Australia, and Canada as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) and is currently being investigated in patients with severe hypertriglyceridemia (sHTG). Patients with FCS and sHTG often present with hepatic steatosis or renal impairment. Because the safety and tolerability of plozasiran in the setting of hepatic and/or renal impairment remains unknown, this study assessed the impact of hepatic or renal impairment on the pharmacokinetics, pharmacodynamics, and safety of a single 25 mg dose of plozasiran.

Despite modest increases in plozasiran exposure, PD responses (APOC3 and TG reduction) were similar between control cohorts and those with moderate-to-severe renal or moderate hepatic impairment. In addition, plozasiran was generally safe and well-tolerated, with no new safety signals identified. Together, these data support the use of 25 mg plozasiran in patients with moderate-to-severe renal impairment or moderate hepatic impairment without dose adjustment. Future trials are needed to help further evaluate plozasiran safety in patients with advanced liver or renal disease.

In an additional oral presentation, the company highlighted a patient case report that suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting TG levels throughout the term of a pregnancy, representing the second case report published on FCS patients in the PALISADE study who discontinued use of plozasiran prior to conception and achieved successful pregnancies. While additional data are needed to define the safety and efficacy of APOC3–targeted therapies during pregnancy, these findings are consistent with the prolonged pharmacodynamic effects of APOC3 inhibition reported in previous PALISADE studies.

Presentation Details:

Session Title: Late Breaking Clinical Abstracts
Title: Pharmacokinetics, Pharmacodynamics, and Safety of Plozasiran in Subjects with Renal or Hepatic Impairment
Date & Time: Tuesday, May 26th, 3:45 - 5:15PM EEST
Presenting Author: Jennifer Hellawell, MD

Session Title: EAS Stage, Outreach and Case Presentations
Title: A Case Report of a Pregnant Woman with Familial Chylomicronemia Syndrome Treated with Plozasiran, a Small Interfering RNA Against APOC3
Date & Time: Tuesday, May 26th, 8:30 - 10:30AM EEST
Presenting Author: Ann Mertens, MD

Today’s presentations will be made available on the EAS Conference website and on the Events and Presentations page under the Investors section of the Arrowhead website.

About REDEMPLO® (plozasiran)

REDEMPLO (plozasiran) is the first and only siRNA treatment approved in these countries that has been studied in both genetically confirmed and clinically diagnosed patients living with FCS. REDEMPLO is a first-in-class siRNA therapeutic designed to suppress the production of apoC-III, a protein produced in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting apoC-III with sustained silencing, REDEMPLO delivers significant reductions in triglyceride levels. REDEMPLO is self-administered via subcutaneous injection once every three months.

The EMA CHMP has adopted a positive opinion recommending the European Marketing Authorization of REDEMPLO (plozasiran), which is already approved by the U.S. Food and Drug Administration, Health Canada, the Australian Therapeutic Goods Administration, and China’s National Medical Products Administration as an adjunct to diet to reduce triglycerides for adults with Familial Chylomicronemia Syndrome (FCS).

Plozasiran is also being investigated in the SHASTA-3 (NCT06347003), SHASTA-4 (NCT06347016), and SHASTA-5 (NCT06880770) Phase 3 studies in adults with severe hypertriglyceridemia and the MUIR-3 (NCT06347133) Phase 3 study in adults with hypertriglyceridemia. In December 2025, plozasiran was granted Breakthrough Therapy designation by the U.S. FDA in severe hypertriglyceridemia.

For more information about REDEMPLO, visit Our Medicines.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.

For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline, products or product candidate or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about our beliefs and expectations regarding the long-term impacts of REDEMPLO® (plozasiran) on patient health and the health care system; our beliefs and expectations regarding the pricing, value, or expected timing for availability of our drugs and drug candidates; and our believes and expectations around the potential uses and value of the TRiM™ platform. These statements are based upon our current expectations and speak only as of the date hereof. Actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties the safety and efficacy of our products and product candidates, pricing and reimbursement decisions related to our products, demand for our products, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

More News From Arrowhead Pharmaceuticals, Inc.

Back to Newsroom

[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company's invest

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global He

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

It has been about a month since the last earnings report for Innospec (IOSP - Free Report) . Shares have lost about 21.8% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Innospec due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Innospec Inc. before we dive into how investors and analysts have reacted as of late.

Key HighlightsEarnings per share (as reported) for the fourth quarter of 2025 improved to $1.91 from a loss of $2.80 a year ago, which was impacted by a UK pension scheme buyout.

Adjusted earnings per share rose 6% to $1.50 from $1.41 a year ago, beating the consensus mark of $1.26.

Revenues for the fourth quarter declined 2% year over year to $455.6 million, missing the Zacks Consensus Estimate of $477 million.

Adjusted EBITDA declined 2% year over year to $55.7 million. Operating income increased 14% to $46.8 million.

Segment PerformanceFuel Specialties revenues rose 1% year over year to $194.1 million, driven by volume growth of 8% offset by an adverse price/mix of 10% and a positive currency impact of 3%. Gross margin expanded 0.3 percentage points to 34.7% and operating income increased 7% to $37.2 million.

Performance Chemicals revenues were flat at $168.4 million as volume declines of 7% were offset by positive price/mix of 3% and currency of 4%. Gross margin compressed 4.6 percentage points to 18.1%, and operating income fell 14% to $17.7 million.

Oilfield Services revenues declined 12% to $93.1 million, reflecting lower U.S. completions and reduced Middle East activity. Gross margin improved 1.8 percentage points to 31.9% on richer sales mix and lower overheads and operating income increased 9% to $8.2 million.

Financials and OutlookOperating cash flow reached $61.4 million with free cash flow of $40.9 million versus $5.1 million in the year-ago quarter. The company ended 2025 with net cash of $292.5 million and no debt.

In the fourth quarter, the adjusted effective tax rate was 24.1%. The company expects a 2026 effective tax rate of roughly 26% and corporate costs of around $20 million per quarter.

Performance Chemicals’ growth is expected to be roughly flat for 2026, with margin improvement building into the second half through pricing mechanisms, manufacturing efficiencies and higher-margin new products.

For Oilfield Services, the company targets 2026 operating income growth with roughly 5-7% full-year revenue growth, led by Middle East activity and the DRA ramp. Fuel Specialties is expected to remain a stable contributor with long-term growth of 2-3%. A historic late-January 2026 winter storm is expected to impact near-term results, with Performance Chemicals' first-quarter operating income around $10-$11 million and Oilfield Services' operating income of around $5-$6 million.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.

The consensus estimate has shifted -23.33% due to these changes.

VGM ScoresAt this time, Innospec has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Charting a somewhat similar path, the stock was allocated a score of B on the value side, putting it in the second quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. It's no surprise Innospec has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Innospec (IOSP - Free Report) , which belongs to the Zacks Chemical - Diversified industry, could be a great candidate to consider.

When looking at the last two reports, this specialty chemicals company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 13.89%, on average, in the last two quarters.

For the last reported quarter, Innospec came out with earnings of $1.5 per share versus the Zacks Consensus Estimate of $1.26 per share, representing a surprise of 19.05%. For the previous quarter, the company was expected to post earnings of $1.03 per share and it actually produced earnings of $1.12 per share, delivering a surprise of 8.74%.

Price and EPS Surprise

For Innospec, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Innospec currently has an Earnings ESP of +2.46%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on May 7, 2026.

Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.

Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

The market expects Innospec (IOSP - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 7. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis specialty chemicals company is expected to post quarterly earnings of $1.02 per share in its upcoming report, which represents a year-over-year change of -28.2%.

Revenues are expected to be $432.15 million, down 2% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 6.01% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Innospec?For Innospec, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +2.46%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that Innospec will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Innospec would post earnings of $1.26 per share when it actually produced earnings of $1.50, delivering a surprise of +19.05%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Innospec doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAmong the stocks in the Zacks Chemical - Diversified industry, Albemarle (ALB - Free Report) , is soon expected to post earnings of $1.24 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of +788.9%. This quarter's revenue is expected to be $1.33 billion, up 23.1% from the year-ago quarter.

Over the last 30 days, the consensus EPS estimate for Albemarle has been revised 18.4% up to the current level. Nevertheless, the company now has an Earnings ESP of +20.12%, reflecting a higher Most Accurate Estimate.

This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Albemarle will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Innospec (IOSP - Free Report) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.42 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +3.45%. A quarter ago, it was expected that this specialty chemicals company would post earnings of $1.26 per share when it actually produced earnings of $1.5, delivering a surprise of +19.05%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Innospec, which belongs to the Zacks Chemical - Diversified industry, posted revenues of $453.2 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 4.87%. This compares to year-ago revenues of $440.8 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Innospec shares have added about 1.5% since the beginning of the year versus the S&P 500's gain of 7.6%.

What's Next for Innospec?While Innospec has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Innospec was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.10 on $457.2 million in revenues for the coming quarter and $4.96 on $1.87 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Chemical - Diversified is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the broader Zacks Basic Materials sector, Sylvamo Corporation (SLVM - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 8.

This company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of -136.8%. The consensus EPS estimate for the quarter has been revised 4.6% higher over the last 30 days to the current level.

Sylvamo Corporation's revenues are expected to be $716 million, down 12.8% from the year-ago quarter.

MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 324

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

Posted by Defense World Staff on Apr 7th, 2026

Azzad Asset Management Inc. ADV grew its holdings in shares of Lincoln Electric Holdings, Inc. (NASDAQ:LECO – Free Report) by 37.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,901 shares of the industrial products company’s stock after purchasing an additional 4,317 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in Lincoln Electric were worth $3,811,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Quent Capital LLC purchased a new position in shares of Lincoln Electric during the 3rd quarter worth $27,000. Frazier Financial Advisors LLC lifted its stake in shares of Lincoln Electric by 3,700.0% during the 3rd quarter. Frazier Financial Advisors LLC now owns 114 shares of the industrial products company’s stock worth $27,000 after purchasing an additional 111 shares during the period. Root Financial Partners LLC purchased a new position in shares of Lincoln Electric during the 3rd quarter worth $31,000. SJS Investment Consulting Inc. lifted its stake in shares of Lincoln Electric by 3,860.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 198 shares of the industrial products company’s stock worth $47,000 after purchasing an additional 193 shares during the period. Finally, Eastern Bank lifted its stake in shares of Lincoln Electric by 109.4% during the 3rd quarter. Eastern Bank now owns 201 shares of the industrial products company’s stock worth $47,000 after purchasing an additional 105 shares during the period. Hedge funds and other institutional investors own 79.61% of the company’s stock.

Lincoln Electric Trading Down 2.3% Shares of LECO opened at $238.05 on Tuesday. The company has a current ratio of 1.82, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $13.05 billion, a P/E ratio of 25.54, a price-to-earnings-growth ratio of 1.51 and a beta of 1.28. The stock’s fifty day simple moving average is $270.38 and its 200 day simple moving average is $250.86. Lincoln Electric Holdings, Inc. has a twelve month low of $161.11 and a twelve month high of $310.00.

Lincoln Electric (NASDAQ:LECO – Get Free Report) last issued its earnings results on Thursday, February 12th. The industrial products company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.12. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.09 billion. Lincoln Electric had a return on equity of 39.35% and a net margin of 12.30%.The business’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period last year, the company posted $2.57 EPS. On average, equities research analysts forecast that Lincoln Electric Holdings, Inc. will post 9.36 earnings per share for the current year.

Lincoln Electric Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Tuesday, March 31st will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 1.3%. The ex-dividend date of this dividend is Tuesday, March 31st. Lincoln Electric’s dividend payout ratio (DPR) is 33.91%.

Wall Street Analyst Weigh In LECO has been the topic of a number of recent analyst reports. Wall Street Zen lowered Lincoln Electric from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings lowered Lincoln Electric from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, March 31st. Barclays reduced their price target on Lincoln Electric from $310.00 to $280.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 1st. Stifel Nicolaus increased their price target on Lincoln Electric from $253.00 to $300.00 and gave the stock a “hold” rating in a research note on Friday, February 13th. Finally, Roth Mkm reissued a “buy” rating and set a $297.00 price target (up from $285.00) on shares of Lincoln Electric in a research note on Tuesday, February 3rd. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Lincoln Electric presently has a consensus rating of “Hold” and an average price target of $296.29.

Get Our Latest Analysis on LECO

Lincoln Electric Profile (Free Report)

Lincoln Electric Holdings, Inc (NASDAQ: LECO) is a global manufacturer and distributor of welding products, robotic welding systems, plasma and oxyfuel cutting equipment, and surface treatment systems. The company’s portfolio encompasses welding consumables such as electrodes and wires, as well as power sources, torches, and automated welding cells. Lincoln Electric also offers software solutions and training services designed to optimize productivity and quality in fabrication and manufacturing operations.

Founded in 1895 by John C.

Featured Articles Five stocks we like better than Lincoln Electric Want to see what other hedge funds are holding LECO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lincoln Electric Holdings, Inc. (NASDAQ:LECO – Free Report).

Receive News & Ratings for Lincoln Electric Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lincoln Electric and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAzzad Asset Management Inc. ADV Has $3.70 Million Stake in Regency Centers Corporation $REG

NEXT HEADLINE »Azzad Asset Management Inc. ADV Increases Stake in Hershey Company (The) $HSY

Investors interested in stocks from the Manufacturing - Tools & Related Products sector have probably already heard of Kennametal (KMT) and Lincoln Electric Holdings (LECO). But which of these two stocks offers value investors a better bang for their buck right now?